|
|
Volumn 1, Issue 1, 2006, Pages 5-6
|
|
Pick the winner designs in phase II cancer clinical trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOPLATIN;
GEMCITABINE;
ANTINEOPLASTIC AGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
IMMUNOSUPPRESSIVE AGENT;
RIBONUCLEOTIDE REDUCTASE;
CANCER GROWTH;
CANCER SURVIVAL;
CLINICAL PRACTICE;
CLINICAL STUDY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DOSAGE SCHEDULE COMPARISON;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
EDITORIAL;
HUMAN;
LUNG NON SMALL CELL CANCER;
METHODOLOGY;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
STATISTICAL ANALYSIS;
DRUG ANTAGONISM;
DRUG COMBINATION;
LUNG TUMOR;
NOTE;
PHASE 2 CLINICAL TRIAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CARBOPLATIN;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE II;
DEOXYCYTIDINE;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
LUNG NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
RIBONUCLEOTIDE REDUCTASES;
TREATMENT OUTCOME;
|
|
EID: 34247862139
PISSN: 15560864
EISSN: 15561380
Source Type: Journal
DOI: 10.1016/s1556-0864(15)31505-7 Document Type: Editorial |
|
Times cited : (9)
|
|
References (5)
|
